The role of statin therapy in the management of cardiomyopathies

Current Atherosclerosis Reports

Volumn 11, Issue 2, 2009, Pages 118-123

  Ramasubbu, Kumudha ^a   Farmer, John A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; RAC PROTEIN; RAS PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RHO FACTOR; ROSUVASTATIN;

ANTIARRHYTHMIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; AUTONOMIC DYSFUNCTION; CARDIOMYOPATHY; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; ENZYME REPRESSION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HORMONAL REGULATION; HUMAN; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; UPREGULATION;

CARDIOMYOPATHIES; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 60849138403     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-009-0019-5     Document Type: Article

References (54)

1. Laufs U, Liao JK: Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep 2003, 5: 372-378.
2. Liao JK: Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002, 110: 285-288.
3. Hanada T, Yoshimura A: Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 2002, 13: 413-421.
4. Delerive P, De Bosscher K, Besnard S, et al.: Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative crosstalk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999, 274: 32048-32054.
5. Brown JH, Del Re DP, SusAman MA: The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 2006, 98: 730-742.
6. Laufs U, Kilter H, Konkol C, et al.: Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovasc Res 2002, 53: 911-920.
7. Sola S, Mir MQ, Lerakis S, et al.: Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006, 47: 332-337.
8. Mozaffarian D, Minami E, Letterer RA, et al.: The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol 2005, 96: 1699-1704.
9. Tousoulis D, Antoniades C, Vassiliadou C, et al.: Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 2005, 7: 1126-1132.
10. Krum H, Ashton E, Reid C, et al.: Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007, 13: 1-7.
11. Takemoto M, Node K, Nakagami H, et al.: Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001, 108: 1429-1437.
12. Chen MS, Xu FP, Wang YZ, et al.: Statins initiated after hypertrophy inhibit oxidative stress and prevent heart failure in rats with aortic stenosis. J Mol Cell Cardiol 2004, 37: 889-896.
13. Habibi J, Whaley-Connell A, Qazi MA, et al.: Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology 2007, 148: 2181-2188.
14. Maack C, Kartes T, Kilter H, et al.: Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003, 108: 1567-1574.
15. Hambrecht R, Fiehn E, Weigl C, et al.: Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 1998, 98: 2709-2715.
16. Scherrer-Crosbie M, Ullrich R, Bloch KD, et al.: Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. Circulation 2001, 104: 1286-1291.
17. Bates K, Ruggeroli CE, Goldman S, Gaballa MA: Simvastatin restores endothelial NO-mediated vasorelaxation in large arteries after myocardial infarction. Am J Physiol Heart Circ Physiol 2002, 283: H768-H775.
18. Laufs U: Beyond lEpid-lowering: effects of statins on endothelial nitric oxide. Eur J Clin Pharmacol 2003, 58: 719-731.
19. Rikitake Y, Liao JK: Rho GTPases, statins, and nitric oxide. Circ Res 2005, 97: 1232-1235.
20. Hattori T, Shimokawa H, Higashi M, et al.: Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 2004, 109: 2234-2239.
21. Kobayashi N, Horinaka S, Mita S, et al.: Critical role of Rho-kinase pathway for cardiac performance and remodeling in failing rat hearts. Cardiovasc Res 2002, 55: 757-767.
22. Indolfi C, Di Lorenzo E, Perrino C, et al.: Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 2002, 106: 2118-2124.
23. Martin J, Denver R, Bailey M, Krum H: In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: Implications for ventricular remodeling. Clin Exp Pharmacol Physiol 2005, 32: 697-701.
24. Saka M, Obata K, Ichihara S, et al.: Pitavastatin improves cardiac function and survival in association with suppression of the myocardial endothelin system in a rat model of hypertensive heart failure. J Cardiovasc Pharmacol 2006, 47: 770-779.
25. Node K, Fujita M, Kitakaze M, et al.: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003, 108: 839-843.
26. Strehlow K, Wassmann S, Bohm M, Nickenig G: Angiotensin AT1 receptor over-expression in hypercholesterolaemia. Ann Med 2000, 32: 386-389.
27. Saijonmaa O, Nyman T, Stewen P, Fyhrquist F: Atorvastatin completely inhibits VEGF-induced ACE upregulation in human endothelial cells. Am J Physiol Heart Circ Physiol 2004, 286: H2096-H2102.
28. Ito M, Adachi T, Pimentel DR, et al.: Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation 2004, 110: 412-418.
29. Cygankiewicz I, Zareba W, Vazquez R, et al.: Relation of heart rate turbulence to severity of heart failure. Am J Cardiol 2006, 98: 1635-1640.
30. Nolan J, Batin PD, Andrews R, et al.: Prospective study of heart rate variability and mortality in chronic heart failure: Results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation 1998, 98: 1510-1516.
31. Pliquett RU, Cornish KG, Peuler JD, Zucker IH: Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 2003, 107: 2493-2498.
32. Vrtovec B, Okrajsek R, Golicnik A, et al.: Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 2005, 11: 684-690.
33. Hanna IR, Heeke B, Bush H, et al.: Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 2006, 3: 881-886.
34. Vyas AK, Guo H, Moss AJ, et al.; MADIT-II Research Group: Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006, 47: 769-773.
35. Goldberger JJ, Subacius H, Schaechter A, et al.; DEFINITE Investigators: Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 2006, 48: 1228-1233.
36. Rauchhaus M, Coats AJ, Anker SD: The endotoxin-lipoprotein hypothesis. Lancet 2000, 356: 930-933.
37. Turunen M, Olsson J, Dallner G: Metabolism and function of coenzyme Q. Biochim Biophys Acta 2004, 1660: 171-199.
38. HargreCves IP: Ubiquinone: cholesterol's reclusive cousin. Ann Clin Biochem 2003, 40: 207-218.
39. Moosmann B, Behl C: Selenoprotein synthesis and sideeffects of statins. Lancet 2004, 363: 892-894.
40. Foody JM, Shah R, Galusha D, et al.: Statins and mortality among elderly patients hospitalized with heart failure. Circulation 2006, 113: 1086-1092.
41. Mozaffarian D, Nye R, Levy WC: Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004, 93: 1124-1129.
42. Folkeringa RJ, Van Kraaij DJ, Tieleman RG, et al.: Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail 2006, 12: 134-138.
43. Go AS, Lee WY, Yang J, et al.: Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 2006, 296: 2105-211.
44. Horwich TB, MacLellan WR, Fonarow GC: Statin therapy is associated with improved survival in ischemic and nonischemic heart failure. J Am Coll Cardiol 2004, 43: 642-648.
45. Krum H, Latini R, Maggioni AP, et al.: Statins and symptomatic chronic systolic heart failure: A post-hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol 2007, 119: 48-53.
46. Krum H, Bailey M, Meyer W, et al.: Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: Results of CIBIS II. Cardiology 2007, 108: 28-34.
47. Ray JG, Gong Y, Sykora K, Tu JV: Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005, 165: 62-67.
48. Dickinson MG, Ip JH, Olshansky B, et al.; SCD-HeFT Investigators: Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: Mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 2007, 153: 573-578.
49. Ramasubbu K, Estep J, White DL, et al.: Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008, 51: 415-426.
50. Kjekshus J, Pedersen TR, Olsson AG, et al.: The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997, 3: 249-254.
51. Scirica BM, Morrow DA, Cannon CP, et al.: Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006, 47: 2326-2331.
52. Vrtovec B, Okrajsek R, Golicnik A, et al.: Atorvastatin therapy decreases sudden cardiac death in patients with advanced chronic heart failure: A prospective study. Presented at European Society of Cardiology Congress. Vienna, Austria; September 4, 2007.
53. Kjekshus J, Apetrei E, Barrios V, et al.; the CORONA Group: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357: 2248-2261.
54. GISSI-HF Investigators: Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet 2008, 372: 1231-1239